NYSE: DHR

Danaher (DHR) Stock Analysis & Forecast

Danaher Corporation. Health technology sector, medical specialties industry. Market cap $148.9B.

$211.81−0.69 (−0.3%)

Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.

Gekko Brief

AI summary

Danaher trades at $211.81, down 0.3% on the day but up 19.6% over three months and 9.8% over the past year, holding above both its 50-day ($203.83) and 200-day ($201.93) averages. The GekkoIndex reads 52, placing the stock in the Neutral zone, and price sits just 1.1% above Gekko Fair Value of $209.53.

This week's news centers on Danaher's reaffirmed quarterly cash dividend of $0.40 per share, payable 30 October 2026 to holders of record as of 30 September 2026, alongside valuation commentary suggesting the stock may be undervalued relative to fair-value estimates cited in that coverage. Separately, UBS assumed coverage with a buy rating and a $250 price target, at a time the stock traded near $205.23. Comparative pieces have also weighed Danaher against peers on value grounds.

Attention over the next 20 trading days centers on the 20 October earnings date, which falls just outside a typical holding window; the last report showed EPS of $1.94 against a $1.84 estimate but produced a -10.9% reaction, with average absolute moves around earnings near 6.9%. Consensus among 18 firms leans heavily toward buy ratings, with a target of $229.09. Seasonally, the next 20 trading days have averaged -2.5% over five years, rising in just 1 of those years, a pattern worth noting alongside the current gap to fair value.

Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.

Price vs fair value

Close $211.81200-day averageGekko Fair Value $209.53

Key stats

Market cap
$148.9B
P/E ratio
37.2
Forward P/E
22.5
EPS, TTM
$5.72
Revenue, TTM
$25.11B
Profit margin
16%
Dividend yield
0.69%
Beta
0.81
Volume
8.83M avg 3.55M
1-year return
+9.8%
Typical daily move
±2.6%
Typical 20-day move
±4.6%
50-day average
$203.83
200-day average
$201.93
Next earnings
Oct 20 before open
Shares outstanding
703.0M
52-week range
$160.93$242.80

Danaher swing-trade checklist

Danaher scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $211.81 is above the 50-day ($203.83) and 200-day ($201.93) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    52, Neutral

    Reading 52 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    1.1% above

    Price is within 5% of Gekko Fair Value (1.1% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 30 days

    Next report Oct 20, 2026, 30 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −2.5% on average

    From this point in the calendar, the next 20 trading days averaged −2.5% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Danaher stock chart and price history

Danaher closed at $211.81 on Sep 18, 2026, +9.8% over the past year, inside a 52-week range of $160.93 to $242.80.

Close50-day average200-day averageVolume

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+0.1%
3 months
+19.6%
6 months
+11.4%
1 year
+9.8%
The full DHR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DHR in Gekko

Follow Danaher through every session

Put DHR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track DHR in GekkoFree for 7 days. No credit card required.

About Danaher

Danaher makes and distributes scientific, medical, industrial and commercial products and services on a global scale, working across science and technology fields rather than a single product line. It is best known for grouping this work into instruments, consumables and related services that support research, healthcare diagnosis and resource management.

The company operates through three segments. Life Sciences covers instrumentation such as mass spectrometers, flow cytometry, genomics and lab automation equipment, centrifuges, particle analysis tools and microscopes, along with consumables tied to gene and cell therapy, bioprocessing, and filtration and purification systems; its customers include pharmaceutical and biopharmaceutical firms, food and beverage makers, medical and life sciences companies, universities, medical schools, research institutes and industrial manufacturers. Diagnostics supplies chemistry, immunoassay, microbiology, hematology, molecular, acute care and pathology systems, reagents, consumables, software and support to hospitals, physician offices, reference labs and other care settings. Environmental & Applied Solutions provides instruments, software, consumables and disinfection systems for treating and managing different water types, plus tools for color and appearance management, packaging quality, printing, marking, coding and traceability for consumer, pharmaceutical and industrial goods.

Danaher's shares are listed on the NYSE under the ticker DHR.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
danaher.com

Danaher GekkoIndex: the smart money zone

Danaher’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52, in the Neutral zone, down 11.3 points over five sessions.

010052Neutral

Down 11.3 points over five sessions, from the Accumulation zone.

Reading for Sep 18, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying48+1.0%+1.6%+2.9%+2.4%
Accumulation2230.0%0.0%+0.4%−1.2%
Neutral (current zone)373−0.1%−0.3%−1.0%−1.5%
Distribution17−0.1%+1.6%+1.8%+1.0%
Selling1Too few readings yet

Average DHR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the DHR price, zone by zone.Track DHR in Gekko

Is Danaher stock overvalued? Gekko Fair Value

Danaher trades 1.1% above Gekko Fair Value of $209.53, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Danaher shares are worth, recalculated every trading day.

$209.53

Gekko Fair Value, Sep 19, 2026

1.1% above fair value · About fair value

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open DHR in Gekko

Danaher insider and Congress trading

No open-market insider purchases were filed for Danaher, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for DHR in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every DHR insider filing, plotted on the chart in Gekko.Open DHR in Gekko

Congress trades last 90 days

No trades in DHR were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for DHR, plotted on the chart in Gekko.Open DHR in Gekko

Buybacks

Danaher has been buying back its own shares.

Bought back, quarter ended Jun 26, 2026
$885.0M
As a share of market cap
0.59%
Trailing four quarters
$2.90B

From company filings.

Hedge funds and billionaires quarter ended Jun 30

9of the funds Gekko tracks hold DHR.

4added3opened2trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Danaher earnings: next date and track record

Danaher reports on Oct 20, 2026, before the open (30 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±6.9%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−5.9%Oct ’24−10.0%Jan ’25+6.1%Apr ’25+5.2%Jul ’25+4.7%Oct ’25−6.8%Jan ’26−5.9%Apr ’26−10.9%Jul ’26

Last earnings call, Jul 21, 2026 AI summary

What they said
Danaher reported Q2 2026 sales of $6.3 billion with core revenue up 3% YoY (4.5% excluding respiratory testing, a 150bps acceleration from Q1). Life sciences delivered its strongest quarter in several years, diagnostics performed well, and bioprocessing showed robust order trends despite timing impacts. High single-digit earnings growth was driven by improved portfolio performance and productivity initiatives. The earlier-than-expected close of the Masimo acquisition supported raised full-year guidance.
Guidance
Management raised full-year adjusted EPS guidance, supported by the earlier-than-expected Masimo acquisition close. They expect accelerating revenue and earnings growth in the second half of 2026 and beyond, citing improving end market momentum and strong secular growth drivers.
ReportedEPSSurpriseRevenueSurpriseMove
Jul 21, 2026$1.94
est $1.84
+5.4%$6.27B
est $6.12B
+2.4%−10.9%
Apr 21, 2026$2.06
est $1.94
+6.2%$5.95B
est $5.98B
−0.5%−5.9%
Jan 28, 2026$2.23
est $2.19
+1.8%$6.84B
est $6.81B
+0.4%−6.8%
Oct 21, 2025$1.89
est $1.72
+9.9%$6.05B
est $6.00B
+0.9%+4.7%
Jul 22, 2025$1.80
est $1.64
+9.8%$5.94B
est $5.84B
+1.7%+5.2%
Apr 22, 2025$1.88
est $1.63
+15.3%$5.74B
est $5.57B
+3.0%+6.1%
Jan 29, 2025$2.14
est $2.14
0.0%$6.54B
est $6.45B
+1.4%−10.0%
Oct 22, 2024$1.71
est $1.57
+8.9%$5.80B
est $5.59B
+3.8%−5.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Danaher stock forecast and analyst price targets

Analysts’ average 12-month price target for Danaher is $229.09, +8.2% from the last close, from 18 firms rating the stock in the last 90 days.

$229.09consensus 12-month target, +8.2% from the last close
Low $195High $250
Buy16
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 18 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Sep 13UBSBuy, initiated$250+18.0%
Aug 4BarclaysBuy, maintained$230+8.6%
Jul 30Morgan StanleyBuy, maintained$220+3.9%
Jul 27Morgan StanleyBuy, maintained$220+3.9%
Jul 27JefferiesBuy, maintained$210−0.9%
−1.0%average 20-day move after past Neutral readings
−2.5%average move over the next 20 trading days in the last 5 years
±2.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Danaher seasonality: the next 20 trading days

Over the next 20 trading days from Sep 19, Danaher averaged −2.5% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−6.1%2021−6.8%2022−6.3%2023−1.6%2024+8.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−3.5%0 of 5
Next 10 trading days−0.8%2 of 5
Next 15 trading days−2.7%1 of 5
Next 20 trading days−2.5%1 of 5
Next 30 trading days−5.8%1 of 5

For scale, DHR’s typical 20-trading-day move in either direction is about 4.6%.

Danaher market cap and key statistics

Danaher’s market cap is $148.9B, with a P/E ratio of 37.2 and revenue of $25.11B over the last twelve months.

Valuation

Market cap
$148.9B
P/E ratio
37.2
Forward P/E
22.5
EPS, TTM
$5.72
Gekko Fair Value
$209.53

Trading

Volume
8.83M
Avg volume, 20 days
3.55M
52-week high
$242.80
52-week low
$160.93
Shares outstanding
703.0M

Financials

Revenue, TTM
$25.11B
Profit margin
16%
Return on equity
7.6%
Quarterly earnings growth, YoY
+59.7%

Risk and income

Beta
0.81
Typical daily move
±2.6%
Typical 20-day move
±4.6%
Dividend yield
0.69%

Danaher stock news this week

Coverage of Danaher this week reads positive: 3 positive, 1 neutral and 0 negative headlines.

News sentiment positive

Danaher peers

Danaher’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.8%Distribution17.1% above
ABTAbbott Laboratories+0.8%Accumulation15.5% below
ISRGIntuitive Surgical+3.1%Neutral12.3% above
MDTMedtronic−0.2%Neutral24.7% below
SYKStryker−1.0%Buying17.1% below
BSXBoston Scientific+0.6%Accumulation35.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

Danaher stock FAQ

What is Danaher’s market cap?

Danaher’s market cap is $148.9B at the Sep 18, 2026 close of $211.81, with 703.0M shares outstanding. The shares trade on a P/E ratio of 37.2.

What is the Danaher stock forecast?

The consensus analyst 12-month price target for Danaher is $229.09, +8.2% from the last close. Of the 18 firms that rated the stock in the last 90 days, 16 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Danaher stock overvalued or undervalued?

On Gekko’s estimate Danaher is about fair value: the Sep 18, 2026 close of $211.81 is 1.1% above Gekko Fair Value of $209.53. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Danaher report earnings next?

Danaher is expected to report on Oct 20, 2026, before the market opens (30 days away). Analysts expect earnings of $1.91 per share on revenue of $6.55B. Danaher beat the earnings estimate in 7 of its last 8 reports, moving 6.9% on average across the report.

What is Danaher’s 52-week high and low?

Danaher’s 52-week high is $242.80 and its 52-week low is $160.93; it closed at $211.81 on Sep 18, 2026, +9.8% over the past year.

Is Danaher stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Danaher the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,349 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.